The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients

[1]  Robin L. Jones,et al.  Methylated NEUROD1 Promoter is a Marker for Chemosensitivity in Breast Cancer , 2008, Clinical Cancer Research.

[2]  Masaru Shinozaki,et al.  Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors , 2008, Breast Cancer Research.

[3]  Xin Hu,et al.  Correlation between CpG methylation profiles and hormone receptor status in breast cancers , 2007, Breast Cancer Research.

[4]  P. Paterlini-Bréchot,et al.  Circulating tumor cells (CTC) detection: clinical impact and future directions. , 2007, Cancer letters.

[5]  D. Hua,et al.  Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. , 2006, Cancer letters.

[6]  Qinghua Feng,et al.  Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Mavroudis,et al.  Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. , 2006, Clinical biochemistry.

[8]  D. Mavroudis,et al.  Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Jimeno,et al.  Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. O’Day,et al.  Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. , 2006, Cancer research.

[11]  E. van Marck,et al.  Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. , 2006, Clinical breast cancer.

[12]  Liying Zhang,et al.  Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients , 2006, Breast Cancer Research and Treatment.

[13]  L. Kiesel,et al.  HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients , 2006, Clinical Cancer Research.

[14]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[15]  N. Lane,et al.  Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. , 2005, Cytotherapy.

[16]  T. Ratliff.  Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. , 2005, The Journal of urology.

[17]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Martin Widschwendter,et al.  Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. , 2005, Cancer research.

[19]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[20]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[21]  J. Califano,et al.  Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer , 2004, Cancer Research.

[22]  Martin Widschwendter,et al.  Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.

[23]  K. Pantel,et al.  Detection and Characterization of Circulating Microsatellite‐DNA in Blood of Patients with Breast Cancer , 2004, Annals of the New York Academy of Sciences.

[24]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[25]  A. Cheung,et al.  Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. , 2004, Gynecologic oncology.

[26]  C. Moon,et al.  Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer , 2004, Clinical Cancer Research.

[27]  A. Harris,et al.  Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR , 2004, British Journal of Cancer.

[28]  M. Widschwendter,et al.  DNA Methylation in Serum and Tumors of Cervical Cancer Patients , 2004, Clinical Cancer Research.

[29]  M. Widschwendter,et al.  DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.

[30]  Martin Widschwendter,et al.  DNA methylation and breast carcinogenesis , 2002, Oncogene.

[31]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[32]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[33]  A. Giuliano,et al.  Microsatellite Alterations Detected in the Serum of Early Stage Breast Cancer Patients , 2001, Annals of the New York Academy of Sciences.

[34]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[35]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[36]  K. Miller,et al.  Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. , 2000, Cancer research.

[37]  J. Goeminne,et al.  Pitfalls in the detection of disseminated non-hematological tumor cells. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[39]  V. Vasioukhin,et al.  The Origin and Mechanism of Circulating DNA , 2000, Annals of the New York Academy of Sciences.

[40]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[41]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[42]  R. Cote,et al.  Detection and clinical importance of micrometastatic disease. , 1999, Journal of the National Cancer Institute.

[43]  Jose M. Silva,et al.  Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. , 1999, Cancer research.

[44]  M. Provencio,et al.  Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients , 1999, British Journal of Cancer.

[45]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[46]  I. Stein.  Nonmalignant Diseases , 2002, Bone Marrow Transplantation.

[47]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[48]  H. Leonhardt,et al.  DNA methylation, nuclear structure, gene expression and cancer , 2000, Journal of cellular biochemistry. Supplement.

[49]  W. Lau,et al.  Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. , 1999, Cancer research.

[50]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[51]  M. Spielmann,et al.  [CA 15-3 and breast cancer]. , 1994, La Revue de medecine interne.

[52]  M. Spielmann,et al.  CA 15-3 et cancers du sein , 1994 .